Abstract:Graphical Beneficial and harmful effects of IL22 in the intestine. IL‐22 is produced by various immune cells at the intestinal epithelium. Here, it acts on enterocytes by binding to the IL‐22 receptor complex to initiate its effects. These include inducing cell proliferation/tumorigenesis, wound healing, and induction of mucins by Goblet cells and antimicrobial peptides by Paneth cells. If produced in excessive amounts, these antimicrobial peptides may damage the intestinal epithelium and reduce microbial diversity. IL‐22 induces tight junction proteins, modulating epithelial barrier permeability. IL‐22 also induces Paneth cells differentiation in humans (image created with Biorender). Interleukin‐22 (IL‐22) is an important cytokine in the intestinal environment. IL‐22 is mainly produced by immune cells and targeted at nonimmune cells such as epithelial and stromal cells in a broad array of tissues such as ‐but not restricted to‐ the liver and adipose tissue. IL‐22 therefore connects immune functions with metabolic functions of the host, and since it is induced by the microbiota, connects host functioning to the outside environment. IL‐22 induces epithelial cell proliferation aiding in rapid epithelium regeneration and wound healing. Additionally, IL‐22 activates antiapoptotic genes and DNA damage response pathways, enhancing epithelial cell survival. Recently, it has also been shown that IL‐22 induces Paneth cell differentiation in humans. However, IL‐22 can also contribute to intestinal epithelium damage and reduces microbial diversity in the intestine directly or indirectly by inducing excessive antimicrobial peptide production by epithelial cells. Moreover, IL‐22 enhances angiogenesis and may therefore support tumorigenesis in the intestine. In conclusion, it appears that whether IL‐22 has a beneficial or harmful effect in the mammalian intestine largely depends on its regulation. This review aims to provide a comprehensive overview of the current literature and emphasizes that IL‐22 signaling outcome depends on the timing and duration of IL‐22 production, the presence of it regulators such as IL‐22BP, and the specific location of the cytokine production in the gastrointestinal tract.

IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine

The role of the IL-22/IL-22R1 axis in cancer

IL-22 Signaling in the Tumor Microenvironment

IL-18 Production Downstream of the Nlrp3 Inflammasome Confers Protection against Colorectal Tumor Formation

IL-22BP controls the progression of liver metastasis in colorectal cancer

The Pathogenic Roles of IL-22 in Colitis: Its Transcription Regulation by Musculin in T Helper Subsets and Innate Lymphoid Cells

The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway

IL-22 Binding Protein (IL-22BP) in the Regulation of IL-22 Biology

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy

IL-22 is related to development of human colon cancer by activation of STAT3

The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity

The role of IL-22 in cancer

The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer

The role of interleukin‐22 in mammalian intestinal homeostasis: Friend and foe

Interleukin 22 Expands Transit-Amplifying Cells While Depleting Lgr5+ Stem Cells via Inhibition of Wnt and Notch Signaling

Interleukin-1 (IL-1) and the inflammasome in cancer

Targeting inflammasome/IL-1 pathways for cancer immunotherapy

An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc mutation-driven intestinal tumorigenesis

Abstract 5330: Intestine-specific homeobox edits macrophage polarization in the disease microenvironment by activating inflammasome activity

Microbiota-induced Activation of Epithelial IL-6 Signaling Links Inflammasome-Driven Inflammation with Transmissible Cancer

IL-22(+)CD4(+) T Cells Promote Colorectal Cancer Stemness Via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L.